传染科

订阅

MedSci主页 / 所有栏目 / 传染科

J Clin Invest：SARS-CoV-2感染恢复的患者体内出现持续细胞免疫失调

2021-01-30 MedSci原创 MedSci原创

SARS-COV-2
关注

SARS-CoV-2会引起多种病理表现，导致较高的死亡率，需要了解疾病的发病机制，为疫苗设计提供信息，并对潜在的免疫特征进行研究。近日，发表于J Clin Invest的一项研究中，研究人员探究了住院

SARS-CoV-2会引起多种病理表现，导致较高的死亡率，需要了解疾病的发病机制，为疫苗设计提供信息，并对潜在的免疫特征进行研究。近日，发表于J Clin Invest的一项研究中，研究人员探究了住院和非住院患者的免疫细胞亚群，结果显示SARS-CoV-2感染后患者免疫失调的时间较长，需要更多的研究来调查患者免疫失调的情况。

住院患者的T细胞活化标志物（CD69、OX40、HLA-DR和CD154）频率增加，其他T细胞活化/耗竭标志物（PD-L1和TIGIT）在住院和非住院患者中仍然升高。B细胞具有类似的激活/耗竭模式，住院期间CD69和CD95的频率增加，随后非住院个体的PD1频率增加。有趣的是，在非住院的纵向样本中，这些变化中的许多变化随着时间的推移而增加，表明SARS-CoV-2感染后免疫失调的时间很长。在非住院患者中发现T细胞活化/耗竭的变化与年龄呈正相关。严重感染者的活化和耗竭标志物表达增加。

图 ICU患者中CD4+T细胞、CD8+T细胞和B细胞标志物表达激活或衰竭的频率

综上所述，这些数据表明，SARS-CoV-2感染后免疫失调的时间较长，这突出表明需要进行更多的研究，调查疗养者的免疫失调情况。

 

原始出处：

 

Jacob K Files, Sushma Boppana, et al., Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest. 2021 Jan 4;131(1):e140491. doi: 10.1172/JCI140491.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937987, encodeId=2472193e98786, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Sep 01 17:58:54 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051632, encodeId=cc7b2051632d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 05 02:58:54 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321253, encodeId=51c913212539e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407635, encodeId=fd7e140e635b4, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-09-01 hukaixun

    #SARS-CoV#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1937987, encodeId=2472193e98786, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Sep 01 17:58:54 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051632, encodeId=cc7b2051632d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 05 02:58:54 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321253, encodeId=51c913212539e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407635, encodeId=fd7e140e635b4, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-05-05 xiangyuzhou971

    #EST#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1937987, encodeId=2472193e98786, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Sep 01 17:58:54 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051632, encodeId=cc7b2051632d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 05 02:58:54 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321253, encodeId=51c913212539e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407635, encodeId=fd7e140e635b4, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-02-01 小刀医生

    #SARS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1937987, encodeId=2472193e98786, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Sep 01 17:58:54 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051632, encodeId=cc7b2051632d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed May 05 02:58:54 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321253, encodeId=51c913212539e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407635, encodeId=fd7e140e635b4, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Mon Feb 01 04:58:54 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-02-01 tulenzi

    #细胞免疫#

    0

相关资讯

创新性SARS-CoV-2阻断剂可完全防止细胞感染

生物制药公司Formycon AG及其学术伙伴慕尼黑工业大学Johannes Buchner教授共同发表了有关创新性SARS-CoV-2阻断剂FYB207的最新结果。

唾液和鼻咽拭子核酸检测的比较，核酸检测捅鼻子还是用唾液？

鉴于其易用性和良好的诊断性能，唾液NAAT是鼻咽拭子NAAT的一个有吸引力的替代选择，并可能显著提高大规模的检测工作的效率。

Ann Neurol：SARS-CoV-2罕见并发症-小儿缺血性卒中

与成人一样，卒中是SARS-CoV-2患儿罕见的并发症，仅4.7％的缺血性卒中患儿检出SARS-CoV-2阳性。

Sci Immunol：CD8+ T细胞对新冠病毒感染反应的多重分子特性

重症COVID-19患者的SARS-CoV-2反应CD8+ T细胞的耗竭特征受损？

J Clin Invest：新冠肺炎患者恢复期时体内抗SARS-CoV-2中和抗体的水平变化及相关因素

自2019年底至今，新冠病毒（SARS-CoV-2）肆虐全球。为了控制SARS-CoV-2的感染，多家机构正在紧锣密鼓地研制SARS-CoV-2疫苗。SARS-CoV-2特异性抗体可预防再感染和疾病，

Clinica Chimica Acta： IgA在SARS-CoV-2感染早期的作用？

病毒基因组序列分析显示从中国武汉获得的肺炎患者呼吸道样本中分离出一种新型冠状病毒(SARS-CoV-2)。